SAMSUNG EPISHOLDINGS CO LTD
Samsung Epis Holdings Co., Ltd., a biotechnology company, manage the portfolio of biopharmaceutical products. The company was founded in 2025 and is based in Incheon, South Korea.
SAMSUNG EPISHOLDINGS CO LTD (0126Z0) - Net Assets
Latest net assets as of : ₩- KRW
Based on the latest financial reports, SAMSUNG EPISHOLDINGS CO LTD (0126Z0) has net assets worth ₩- KRW as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩-) and total liabilities (₩-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SAMSUNG EPISHOLDINGS CO LTD - Net Assets Trend (None–None)
This chart illustrates how SAMSUNG EPISHOLDINGS CO LTD's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SAMSUNG EPISHOLDINGS CO LTD (None–None)
The table below shows the annual net assets of SAMSUNG EPISHOLDINGS CO LTD from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to SAMSUNG EPISHOLDINGS CO LTD's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
SAMSUNG EPISHOLDINGS CO LTD Competitors by Market Cap
The table below lists competitors of SAMSUNG EPISHOLDINGS CO LTD ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Kubera Gold Corp.
V:KBRA
|
$3.26 Million |
|
Neith Corporation
TWO:6236
|
$3.26 Million |
|
UJOGF
OTCQB:UJOGF
|
$3.26 Million |
|
Petrol d.d.
LSE:0M0P
|
$3.26 Million |
|
Polaris Investama Tbk
JK:PLAS
|
$3.26 Million |
|
Cell Impact AB
ST:CI
|
$3.25 Million |
|
CADOGAN ENERGY SOLUTIONS
F:CPD
|
$3.25 Million |
|
FUXING CHINA GRP SD 5
F:3FU1
|
$3.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SAMSUNG EPISHOLDINGS CO LTD's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares SAMSUNG EPISHOLDINGS CO LTD's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently SAMSUNG EPISHOLDINGS CO LTD utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares SAMSUNG EPISHOLDINGS CO LTD's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $209,689,906,881
- Average return on equity (ROE) among peers: -10.47%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SAMSUNG EPISHOLDINGS CO LTD (0126Z0) | ₩- | N/A | N/A | $3.26 Million |
| ORIENTBIO Inc. (002630) | $67.35 Billion | -2.60% | 1.21x | $28.10 Million |
| Green Cross (005250) | $282.15 Billion | 18.83% | 0.53x | $228.88 Million |
| Green Cross Holdings Preference Shares (005257) | $1.44 Trillion | 3.01% | 0.78x | $410.72 Million |
| Pharmicell (005690) | $9.90 Billion | -119.73% | 2.00x | $438.14 Million |
| GeneOne Life Science Inc (011000) | $39.74 Billion | 0.00% | 0.49x | $53.78 Million |
| HLB Co. Ltd (028300) | $77.24 Billion | -21.40% | 1.44x | $4.11 Billion |
| Daesung Microbiological Labs. Co. Ltd (036480) | $25.09 Billion | 18.13% | 0.29x | $14.92 Million |
| Seoulin Bioscience Co.Ltd (038070) | $51.49 Billion | 4.00% | 0.38x | $27.72 Million |
| Hyundai Bioscience Co. Ltd (048410) | $39.30 Billion | 0.00% | 0.56x | $899.28 Million |
| iNtRON Biotechnology Inc (048530) | $64.96 Billion | -4.91% | 0.37x | $83.99 Million |